NEW YORK – On Friday, Johnson & Johnson (NYSE: JNJ) said it is negotiating with plaintiffs’ lawyers who have opposed the company’s proposed settlement of lawsuits alleging its baby powder and other talc products caused cancer, seeking to eliminate holdouts to the deal.
Johnson & Johnson has announced plans to finalize a $6.48 billion global settlement through the bankruptcy of a subsidiary company after earlier efforts were rebuffed twice by federal courts.
Johnson & Johnson says the majority of claimants support its settlement offer. But it has paused a vote count for a short time so that it can gather additional votes from plaintiffs who have until recently opposed the deal.
“We have agreed to a short extension of the certification timeline,” said Erik Haas, J&J’s worldwide vice president of litigation, in a statement. “This will allow these plaintiffs’ attorneys time to speak to their claimants to now consider supporting the plan.”
Andy Birchfield, a lawyer who has led opposition to J&J’s proposed bankruptcy settlement, said he welcomed negotiations with claimants but is prepared to resist another Chapter 11 filing.
“Our ultimate objective is fair compensation in a timely manner for ovarian cancer victims. If J&J is becoming more reasonable by negotiating with some claimants, we applaud that,” Birchfield said.
“For now, we are continuing to fight for our clients and if J&J chooses the bankruptcy route for the third time, we will oppose it and we believe the company will fail.”
Johnson & Johnson (NYSE: JNJ) plans to place a subsidiary into bankruptcy if it gets at least 75% of the talc claimants to vote for its settlement proposal.
The bankruptcy settlement would end all talc lawsuits alleging that J&J products cause ovarian cancer, and it would prevent similar cases from being filed in the future.
Johnson & Johnson faces lawsuits from more than 62,000 plaintiffs alleging that its baby powder and other talc products were contaminated with asbestos and caused ovarian and other cancers. J&J denies the allegations and has said that its products are safe, do not contain asbestos, and do not cause cancer.
The current proposed bankruptcy settlement focuses on claims involving ovarian and other gynecological cancers, building on the company’s previous settlement outside of Chapter 11 proceedings of most lawsuits alleging that its talc caused mesothelioma, a deadly cancer linked to asbestos exposure.
By using a subsidiary’s bankruptcy to file for bankruptcy, Johnson & Johnson seeks to force all plaintiffs into one settlement – without requiring J&J itself to file bankruptcy.
Bankruptcy judges can enforce global settlements that permanently halt all related lawsuits and forbid new ones.
Outside of bankruptcy, any settlement Johnson & Johnson reached with some clients would still leave holdouts or future plaintiffs with the right to sue – and leave the company exposed to potential multibillion-dollar verdicts that encouraged it to pursue a bankruptcy settlement in the first place.
Johnson & Johnson (NYSE: JNJ) has prevailed in many of the ovarian cases tried to date. But the litigation has also resulted in some large verdicts for plaintiffs, including a $2.12 billion award in favor of 22 women who blamed their ovarian cancer on asbestos in J&J talc.
(Source: Reuters)
